Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 74

Sort by

Sort Order Select

Journal Articles

Nanobody-based Naturally Selected CD7-Targeted CAR-T Therapy for Acute Myeloid Leukemia

Peihua Lu, Xian Zhang, Junfang Yang, Jingjing Li, Liyuan Qiu, Meiwei Gong, Hui Wang, Jiaqi Chen, Hongxing Liu, Min Xiong, Ying Liu, Lin Wang

Blood blood.2024024861.

https://doi.org/10.1182/blood.2024024861

Published: 2024

Includes: Supplemental data

Journal Articles

CDK9 phosphorylates RUNX1 to promote megakaryocytic fate in megakaryocytic-erythroid progenitors

Nayoung Kwon, Yi-Chien Lu, Evrett N. Thompson, Rubia Isler Mancuso, Lin Wang, Ping-Xia Zhang, Diane S. Krause

Blood (2024) 144 (17): 1800–1812.

https://doi.org/10.1182/blood.2024023963

Published: 2024

Includes: Supplemental data

Journal Articles

Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity

Blood (2024) 143 (26): 2722–2734.

https://doi.org/10.1182/blood.2023023447

Published: 2024

Includes: Supplemental data

Journal Articles

Comparative Effectiveness of Axicabtagene Ciloleucel Vs Historical Standard-of-Care in Patients with Relapsed or Refractory Follicular Lymphoma: An Analysis of CIBMTR and SCHOLAR-5 Data

Blood (2023) 142 (Supplement 1): 2121.

https://doi.org/10.1182/blood-2023-178629

Published: 2023

Journal Articles

Anti-BCMA Dual Epitope-Binding CAR-Marrow Infiltrating Lymphocytes (MILs) Could Offer a Potent Innovative Immunotherapeutic Tool Against Multiple Myeloma

Manh-Cuong Vo, Sung-Hoon Jung, Van-Tan Nguyen, Van-Dinh-Huan Tran, Sang-Ki Kim, Woo Kyun Bae, Hyeoung-Joon Kim, Lin Wang, Je-Jung Lee

Blood (2023) 142 (Supplement 1): 6811.

https://doi.org/10.1182/blood-2023-188428

Published: 2023

Journal Articles

Real-World Outcomes of Brexucabtagene Autoleucel (brexu-cel) for Relapsed or Refractory (R/R) Adult B-Cell Acute Lymphoblastic Leukemia (B-cell ALL): Evidence from the CIBMTR Registry

Blood (2023) 142 (Supplement 1): 1029.

https://doi.org/10.1182/blood-2023-177693

Published: 2023

Journal Articles

Analytical and Clinical Validation of Duoseq, a Novel Assay for Rapid, on-Site Clinical DNA and RNA Sequencing of Hematologic Malignancies

Eric D. Hsi, Magdalena Czader, Brian T. Hill, Elizabeth Thacker, Lin Wang, Christopher Giauque, Andrea Vrydaghs, Matt Sperling, Jordan Bouldin, Robert Erno, Lanie Happ, Clayton Parker, Cassandra L. Love, Jennifer Shingleton, Sandeep Dave

Blood (2023) 142 (Supplement 1): 3670.

https://doi.org/10.1182/blood-2023-189030

Published: 2023

Journal Articles

High Efficacy and Safety of Nanobody Based Anti-BCMA CAR-T Cell Therapy in Treating Patients with Relapsed or Refractory Multiple Myeloma

Xian Zhang, Lin Wang, Junfang Yang, Jingjing Li, Hongxing Liu, Jianqiang Li, Peihua Lu

Blood (2023) 142 (Supplement 1): 2107.

https://doi.org/10.1182/blood-2023-185271

Published: 2023

Journal Articles

Early Intervention and Favorable Biologic Effects of Personalized Neoantigen Vaccines on the Tumor Immune Microenvironment in Smoldering Waldenstrom Macroglobulinemia

Szymon Szymura, Soungchul Cha, Lin Wang, Tiantian Zhang, Zhenyuan Dong, Aaron Anderson, Elizabeth Oh, Zhe Wang, Vincent Lee, Sapna Parshottham, Sheetal Rao, Jasper B Olsem, Brandon N Crumpton, Hans C. Lee, Elisabet E. Manasanch, Sattva S. Neelapu, Sheeba K. Thomas, Larry W. Kwak

Blood (2023) 142 (Supplement 1): 212.

https://doi.org/10.1182/blood-2023-182448

Published: 2023

Journal Articles

Prospective Molecular Characterization of Multiple Myeloma Patient Samples Identifies High-Risk Patients and Informs Treatment Sequences through Resistance Mechanisms to Immunotherapies

Phillip Pham, Parvathi Sudha, Lin Wang, Wen Niu, Cameron Morgan, Cameron Ligocki, Ramzi Al-Azzawi, Reynold Ly, Francesco Vetrini, Magdalena Czader, Marwan Tayeh, Mohammad Abu Zaid, Kelvin P. Lee, Attaya Suvannasankha, Rafat Abonour, Brian A. Walker

Blood (2023) 142 (Supplement 1): 4738.

https://doi.org/10.1182/blood-2023-180116

Published: 2023

Journal Articles

Real-World Evidence in the United States (US) of the Impact of Bridging Therapy Prior to Axicabtagene Ciloleucel (Axi-Cel) for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma (R/R LBCL)

Blood (2023) 142 (Supplement 1): 103.

https://doi.org/10.1182/blood-2023-175034

Published: 2023

Journal Articles

A Single Institutional Experience Using Avatrombopag to Manage Severe and Refractory Treatment Related Thrombocytopenia in Solid Tumor and Hematologic Malignancy Patients

Linlin Shao, Lu Liu, Yu Hou, Xiaolin Zhang, Lin Wang, Shuqian Xu, Ping Qin, Qiang Song, Jun Peng, Ming Hou, Yan Shi

Blood (2023) 142 (Supplement 1): 5447.

https://doi.org/10.1182/blood-2023-188831

Published: 2023

Journal Articles

Outcomes of Axicabtagene Ciloleucel in Comparison with Chemoimmunotherapy (CIT) in an Elderly Population for Treatment of Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) after Two or More Lines of Prior Therapy

Blood (2022) 140 (Supplement 1): 1852–1855.

https://doi.org/10.1182/blood-2022-162421

Published: 2022

Journal Articles

Iron Overload and Iron-Induced Microbiome Changes May Affect Lymphoid Levels Post Bone Marrow Transplant and Graft-Versus-Host Disease Survival in Mice

Annie Qiu, Lin Wang, Flavia Dei Zotti, Krystalyn E Hudson, Eldad A. Hod, Francesca La Carpia

Blood (2022) 140 (Supplement 1): 2465–2466.

https://doi.org/10.1182/blood-2022-167300

Published: 2022

Journal Articles

Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL/LBL: first-in-human phase 1 clinical trial

Peihua Lu, Ying Liu, Junfang Yang, Xian Zhang, Xiao Yang, Hui Wang, Lin Wang, Qinglong Wang, David Jin, Jianqiang Li, Xiaojun Huang

Blood (2022) 140 (4): 321–334.

https://doi.org/10.1182/blood.2021014498

Published: 2022

Includes: Supplemental data

Journal Articles

High Effectiveness and Safety of Anti-CD7 CAR T-Cell Therapy in Treating Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL)

Junfang Yang, Xian Zhang, Ying Liu, Xiao Yang, Hui Wang, Lin Wang, Jianqiang Li, Peihua Lu

Blood (2021) 138 (Supplement 1): 473.

https://doi.org/10.1182/blood-2021-147667

Published: 2021

Journal Articles

A Clinically Validated Targeted Capture Panel to Identify Translocations, Copy Number Abnormalities, and Mutations in Multiple Myeloma

Blood (2021) 138 (Supplement 1): 2676.

https://doi.org/10.1182/blood-2021-148692

Published: 2021

Journal Articles

Naturally Selected Anti-CD7 CAR-T Cells without Additional Genetic Manipulations As a Potentially Superior Therapy for T-Cell Malignancies

Ying Liu, Weijing Li, Lin Wang, Min Ba, Qinglong Wang, Peihua Lu, Lihong Liu, Jianqiang Li

Blood (2021) 138 (Supplement 1): 1696.

https://doi.org/10.1182/blood-2021-149384

Published: 2021

Journal Articles

Preliminary Safety and Efficacy Results from Precizn-1: An Ongoing Phase 1/2 Study on Zinc Finger Nuclease-Modified Autologous CD34+ HSPCs for Sickle Cell Disease (SCD)

Asif Alavi, Lakshmanan Krishnamurti, Mehrdad Abedi, Isobelle Galeon, David Reiner, Sharon E Smith, Lin Wang, Anne Ramezi, Pablo Rendo, Mark C. Walters

Blood (2021) 138 (Supplement 1): 2930.

https://doi.org/10.1182/blood-2021-151650

Published: 2021

Journal Articles

Cell Cycle Regulates Phosphorylation of RUNX1 to Modulate Megakaryocyte-Erythroid Progenitor Fate Specification

Yi-Chien Lu, PhD, Vanessa M Scanlon, PhD, Juliana Xavier-Ferrucio, PhD, Lin Wang, MS, Alan Friedman, Alan B. Cantor, MD PhD, Diane S. Krause, MD PhD

Blood (2020) 136 (Supplement 1): 15.

https://doi.org/10.1182/blood-2020-141156

Published: 2020

NARROW

Nanobody-based Naturally Selected CD7-Targeted CAR-T Therapy for Acute Myeloid Leukemia

CDK9 phosphorylates RUNX1 to promote megakaryocytic fate in megakaryocytic-erythroid progenitors

Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity

Comparative Effectiveness of Axicabtagene Ciloleucel Vs Historical Standard-of-Care in Patients with Relapsed or Refractory Follicular Lymphoma: An Analysis of CIBMTR and SCHOLAR-5 Data

Anti-BCMA Dual Epitope-Binding CAR-Marrow Infiltrating Lymphocytes (MILs) Could Offer a Potent Innovative Immunotherapeutic Tool Against Multiple Myeloma

Real-World Outcomes of Brexucabtagene Autoleucel (brexu-cel) for Relapsed or Refractory (R/R) Adult B-Cell Acute Lymphoblastic Leukemia (B-cell ALL): Evidence from the CIBMTR Registry

Analytical and Clinical Validation of Duoseq, a Novel Assay for Rapid, on-Site Clinical DNA and RNA Sequencing of Hematologic Malignancies

High Efficacy and Safety of Nanobody Based Anti-BCMA CAR-T Cell Therapy in Treating Patients with Relapsed or Refractory Multiple Myeloma

Early Intervention and Favorable Biologic Effects of Personalized Neoantigen Vaccines on the Tumor Immune Microenvironment in Smoldering Waldenstrom Macroglobulinemia

Prospective Molecular Characterization of Multiple Myeloma Patient Samples Identifies High-Risk Patients and Informs Treatment Sequences through Resistance Mechanisms to Immunotherapies

Real-World Evidence in the United States (US) of the Impact of Bridging Therapy Prior to Axicabtagene Ciloleucel (Axi-Cel) for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma (R/R LBCL)

A Single Institutional Experience Using Avatrombopag to Manage Severe and Refractory Treatment Related Thrombocytopenia in Solid Tumor and Hematologic Malignancy Patients

Outcomes of Axicabtagene Ciloleucel in Comparison with Chemoimmunotherapy (CIT) in an Elderly Population for Treatment of Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) after Two or More Lines of Prior Therapy

Iron Overload and Iron-Induced Microbiome Changes May Affect Lymphoid Levels Post Bone Marrow Transplant and Graft-Versus-Host Disease Survival in Mice

Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL/LBL: first-in-human phase 1 clinical trial

High Effectiveness and Safety of Anti-CD7 CAR T-Cell Therapy in Treating Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL)

A Clinically Validated Targeted Capture Panel to Identify Translocations, Copy Number Abnormalities, and Mutations in Multiple Myeloma

Naturally Selected Anti-CD7 CAR-T Cells without Additional Genetic Manipulations As a Potentially Superior Therapy for T-Cell Malignancies

Preliminary Safety and Efficacy Results from Precizn-1: An Ongoing Phase 1/2 Study on Zinc Finger Nuclease-Modified Autologous CD34+ HSPCs for Sickle Cell Disease (SCD)

Cell Cycle Regulates Phosphorylation of RUNX1 to Modulate Megakaryocyte-Erythroid Progenitor Fate Specification

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only